Antibiotic treatment in patients with febrile neutropenia;Antibiotická léčba pacientů s febrilní neutropenií

Transfuze a Hematologie Dnes

Volumn 8, Issue 1, 2002, Pages 20-24

  Kolar M ^a   Faber, E ^b   Lochmannova Jr J ^c   Papajik T ^b   Hubacek J ^b   Raida, L ^b   Vagnerova I ^a  

^a Military Hospital Olomouc   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antibiotic treatment; Febrile neutropenia; Vancomycin resistant enterococci

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; GREPAFLOXACIN; ITRACONAZOLE; KETOCONAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ENTEROCOCCUS; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; PROGNOSIS;

EID: 0141926720     PISSN: 12135763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 1998; 41 (Suppl D): 1-5.
2. Gaynes R, Edwards J. The National Nosocomial Infection Surveillance (NNIS) System. Nosocomial vancomycin resistant enterococci (VRE) in the United States, 1989-1995: the first 1000 isolates (abstract). In: The Sixth Annual Meeting of The Society for Healthcare Epidemiology of America; April 1996; Washington, DC. Infect Control Hosp Epidemiol 17: P18.
3. Heath CH, Blackmore TK, Gordon DL. Emerging resistance in Enterococcus sp. Med J Aust 1996; 164: 116-20.
4. Kolář M. Antibiotická léčba nozokomiálncinh infekcí. Triton; Praha 2000.
5. Kolář M, Kurašová Y, Látal T, Hejnar P, Faber E, Raida L. Výskyt bakteriálních kmenů izolovaných u neutropenických pacientů a jejich rezistence k antibiotikům. Čas Lḱ čes 1998; 137: 84-8.
6. Nyč O, Kavan P, Lochmann O. Současné možnosti anti-mikrobrí léčby onkologicky nemochého pacienta s febrilní neutropenií. Remedia Klin Mikrobiol 1997; 1: 144-7.
7. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41 (Suppl D): 7-11.
8. Reese RE, Betts RF. A practical approach to infectious diseases. 1996; 4th ed., Little, Brown and Company, Boston Toronto London.
9. Rolston KVI, Raad I, Whimbey E, Bodey GP. The changing spectrum of bacterial infections in febrile neutropenic patients. In: Klastersky JA. Febrile neutropenia, 1997. Springer-Verlag, Berlin Heidelberg.
10. Speller DCE, Lynn WA, Rogers TR. Glycopeptide resistance in gram-positive bacteria. Clin Microbiol Infect 1995; 1: 54-59.
11. Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother 1998; 41 (Suppl D): 95-105.